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Abstract 
Context: Finding the source of adrenocorticotropic hormone (ACTH)-independent 
cortisol-producing adenoma in the patients with subclinical Cushing syndrome (SCS) 
and bilateral adrenal nodules is sometimes challenging. Computed tomography (CT) and 
positron emission tomography are helpful, but adrenal venous sampling (AVS) is the 
gold standard approach. However, interpretation of AVS is important to improve the ac-
curacy of decision-making for surgery. We report a case and review of the literature to 
assess the benefit of using adrenal vein cortisol to metanephrine ratio to determine the 
source of cortisol production in SCS and bilateral nodules.
Evidence Acquisition: Three authors searched PubMed for data on patients with SCS 
who had AVS procedure and measurements of cortisol and catecholamines.
Case Description: A 51-year-old woman with SCS and hypertension crisis presented 
to our clinic. Paraclinical investigations revealed that she had an ACTH-independent 
cortisol-producing adenoma and her CT scan showed bilateral adrenal nodules. After 
AVS, cortisol (high to low) lateralization ratio could not determine the source of cortisol 
production but the cortisol to metanephrine ratio localized the source to the left side, 
which included the larger nodule according to CT measurements. Left adrenalectomy led 
to clinical and paraclinical improvement.
Conclusion: There is a possibility of co-secretion of other steroids accompanied with 
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and interpretation of AVS results based on cortisol values may not help lateralizing the 
source of cortisol production with bilateral adrenal nodules. Therefore, we suggest ap-
plying cortisol to metanephrine ratio with the same gradient (gradient > 2.3, highest to 
lowest concentration) when the source of cortisol production cannot be determined by 
cortisol lateralization ratio.
Key Words: subclinical Cushing, adrenal venous sampling, cortisol to metanephrine ratio
The increased use of imaging modalities has led to 
greater detection of incidental adrenal nodules. Adrenal 
incidentalomas are common, approximately 0.2% in the 
young and up to 7% in people over the age of 70 [1]. 
Physicians must differentiate between a nonfunctional 
versus hormonally active nodule and between benign 
versus malignant nodules, on the basis of imaging and bio-
chemical workup. The majority of adrenal incidentalomas 
are benign and nonfunctional; however, subclinical 
hypercortisolism is present in approximately 5% to 30% 
of adrenal incidentalomas. Subclinical Cushing syndrome 
(SCS) is defined by the presence of biochemical autono-
mous cortisol production without overt symptoms or signs 
of hypercortisolism [2, 3] and other terms for this condi-
tion is mild autonomous cortisol excess/secretion (MACE/
MACS), or autonomous cortisol secretion (ACS) [4]. 
Patients with SCS are at increased risk of comorbidities, 
such as diabetes, osteoporosis, vertebral fractures, hyper-
tension, dyslipidemia, and obesity [5, 6]. Furthermore, 
surgical intervention with an adrenalectomy improves car-
diovascular risk and comorbidities, such as hypertension, 
diabetes, dyslipidemia, and obesity [7-10].
It is sometimes difficult to ascertain the source of cor-
tisol production in SCS. Although one would tend to think 
that the dominant nodule is the one making the excess cor-
tisol, this is often not the case, and the assumption can re-
sult in surgical removal of the wrong adrenal. To localize 
the source of the excess cortisol production, both im-
aging methods and selective adrenal vein sampling (AVS) 
have been used. Adrenal scintigraphy using iodine-168-
labeled 19-iodocholesterol [11-13] and fluorine-18-labeled 
fluorodeoxyglucose (18F-FDG) positron emission tomog-
raphy (PET)/computed tomography (CT) scanning [14] 
are applied to localize the source of cortisol production. 
Selective venous sampling is another method, which is used 
for primary hyperaldosteronism [15], adrenocorticotropic 
hormone (ACTH)-independent Cushing syndrome [16, 
17], SCS [18], and hyperandrogenism [19]. Although scin-
tigraphy and AVS are reported as acceptable methods to lo-
calize the cortisol-producing adenoma [20], these methods 
often give discordant findings [21]. Furthermore, surgical 
approach based on the nodule size is used [16], but the 
accuracy of AVS for surgical decision-making can be very 
important [17, 21].
When AVS is used for evaluation of SCS patients, the 
measurements should be performed after an overnight 
fast and with low-dose (1-2  mg) or high-dose (8  mg) 
dexamethasone the day before the procedure to suppress 
ACTH and minimize the effect of stress on cortisol level. 
In addition, the correct catheter position is important, 
which is based on the adrenal vein (AV) to peripheral vein 
(PV) metanephrine ratio. An AV:PV metanephrine ratio 
greater than 12 indicates correct adrenal vein position and 
successful catheterization [17, 21]. There are 2 usual ap-
proaches to lateralize a cortisol-secreting adenoma. The 
AV:PV cortisol gradient is one method, with a ratio less 
than 3.3 not clinically significant, between 4.1 and 6.4 as-
sociated with adrenal hyperplasia, and greater than 6.5 
consistent with cortisol-producing adenoma [17, 18]. The 
second approach involves a higher to lower cortisol gra-
dient between the 2 adrenal veins. It has been reported 
that a gradient greater than 2.3 proves lateralization and 
less than 2 is associated with bilateral cortisol production 
[17, 21]. However, this is a very narrow window of cortisol 
ratios on which to base a surgical decision of which ad-
renal to remove, and it also does not account for a gradient 
between 2 and 2.3. We present a case to justify the role of 
cortisol to metanephrine ratio as an alternative approach in 
the situation where the current criteria cannot lateralize a 
cortisol-producing adenoma.
Methods
We (3 authors) searched PubMed using the keywords 
subclinical Cushing syndrome, mild autonomous cortisol 
production, adrenal venous sampling for literature that 
included patients with bilateral adrenal nodules and SCS 
who underwent AVS. We selected cases with information 
regarding cortisol and catecholamines (metanephrine, 
normetanephrine, epinephrine/adrenaline, and norepin-
ephrine/noradrenaline) levels of peripheral and adrenal 
veins. We used the side-to-side adrenal vein cortisol con-
centration and cortisol to catecholamines ratio ([cor-
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catecholamines in nondominant adrenal vein]) to deter-
mine the lateralization of cortisol secretion. We measured 
the cortisol to catecholamines lateralization ratio in com-
parison with cortisol, cortisol/aldosterone, and cortisol/ 
dehydroepiandrosterone sulfate (DHEAS) lateralization 
ratio. Patients were deemed to have an acceptable response 
to unilateral adrenalectomy if they developed adrenal in-
sufficiency after unilateral adrenalectomy, serum cortisol 
less than 2 mcg/dL after dexamethasone suppression test, 
or improved clinically (hypertension, obesity, and diabetes).
Case Report
A 51-year-old Caucasian woman presented to the out-
patient endocrinology clinic for evaluation of bilateral 
adrenal masses incidentally diagnosed on CT scan of her 
abdomen during workup for uncontrolled vaginal bleeding. 
Review of system was positive for intermittent flushing 
and hypertensive crisis. On examination, the patient’s 
weight was 268 pounds and body mass index was 37.5 kg/
m2. The patient did not have classic features of Cushing 
syndrome, such as purple abdominal striae or plethora. 
Fasting glucose was 100  mg/dL and her glycated hemo-
globin (HbA1c) was 5.5%. An abdominal CT scan from 
February 2019 revealed 2.3 cm right and 3.5 cm left side 
adrenal nodules (Hounsfield units < 10). On review of a 
previous CT scan of abdomen from 2017, bilateral adrenal 
lesions measuring <1 cm were noted. ACTH-independent 
mild autonomous cortisol secretion was confirmed with 
1  mg overnight dexamethasone suppression test, which 
failed to suppress cortisol (2.9 mcg/dL), along with sup-
pressed baseline ACTH and DHEAS. Plasma fractionated 
metanephrines, plasma renin activity, and plasma aldos-
terone concentration were normal (Table 1). Because there 
were bilateral nodules, AVS was pursued to differentiate 
between a bilateral versus unilateral source of cortisol ex-
cess prior to planning surgical intervention (Table 2). Due 
to concerns of cortisol excess confounding interpretation 
of AVS results, metanephrine levels were used to ascertain 
proper catheterization. Dekkers et  al [22] has suggested 
that the AV:PV metanephrine ratio should be >12 if there is 
adequate catheterization. As shown in Table 2, the AV:PV 
ratio was 60 on the right and 24.5 on the left for this pa-
tient. Cortisol was detected from both sides, 24 μg/dL from 
the right, and 37.4 μg/dL from the left, demonstrating that 
there was not a predominant cortisol-producing nodule 
that was suppressing the contralateral side (cortisol gra-
dient  <  2). However, the cortisol to metanephrine ratio 
was 7.6 on the left, and 2.0 on the right. The left to right 
cortisol to metanephrine ratio of 3.8 was suggestive of 
dominant left side cortisol production. Hence, a decision 
to pursue unilateral left adrenalectomy was taken and 
the patient underwent a successful left adrenalectomy in 
September 2019. An ACTH stimulation test 1 week fol-
lowing surgery showed cortisol levels of 14.7, 21, and 19.1 
mcg/dL at baseline, 30 minutes, and 60 minutes, respect-
ively. After surgery, she was started on a physiologic dose 
of hydrocortisone. Four weeks post-adrenalectomy, blood 
pressure was controlled and her lisinopril was stopped. She 
lost approximately 6 pounds within 3  months after sur-
gery and continued to remain normotensive without any 
antihypertensive. Hydrocortisone was gradually tapered 
off over 5  months post-adrenalectomy, as early discon-
tinuation resulted in symptoms of nausea, abdominal 
Table 1. Biochemical Studies Confirming Autonomous Cortisol Secretion From Adrenal Gland Before Surgery and 
Improvement After Surgery[1, 2, 18, 21]
Diagnostic Workups (Reference Interval) Results
Before Surgery After Surgery 
1-mg overnight dexamethasone suppression test  
Cortisol (<1.8 mcg/dL) [21]  
(Serum dexamethasone level 140 – 295 ng/dL) 
2.9 (293), 3.3 (311)  
6 and 7 months before surgery
< 2 (329), 1.1 (370)  
6 and 12 months after surgery
4-mg dexamethasone suppression test for AVS, cortisol (mcg/dL) 2.9  
24-hour urine free cortisol (< 90 mcg per day) [18] 35  
Plasma ACTH level (9 – 52 pg/mL) [18] 6, < 5 17.5, 17.8 
Plasma DHEAS level (35-430 mcg/dL) 32, 32 26, 23
Late-night salivary cortisol (< 0.145 mcg/dL) [1] or (< 0.17 mcg/
dL) [2] 
0.069, 0.070 0.098 
Aldosterone level (normal 3-16 ng/dL) < 1  
Plasma renin activity (0.25 – 5.82 ng/mL/h) 0.19  
Free normetanephrine/metanephrine (< 0.9/0.5 nmol/L) 0.38/<0.20  
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pain, and diarrhea. After weaning off the hydrocortisone, 
an overnight 1  mg dexamethasone suppression test was 
normal (Table 1). A follow up CT scan of her abdomen in 
December 2019 showed a mild increase in size of the right 
adrenal nodule, from 2.3  cm in maximum dimension to 
3 cm in maximum dimension, but the size remained stable 
at 3 cm in September 2020.
Discussion
This patient had SCS with bilateral adrenal nodules along 
with hypertension and obesity. She improved clinically and 
biochemically with unilateral adrenalectomy. SCS manage-
ment poses a challenge, especially in the setting of bilateral 
adrenal mass. It is important to solve the puzzle of which 
adrenal gland should be removed and avoid permanent ad-
renal insufficiency secondary to bilateral adrenalectomy or 
surgical removal of the wrong adrenal.
The first step in the workup is confirmation of autono-
mous cortisol production. This can be challenging because 
patients with SCS do not demonstrate the clear and con-
tinuous high cortisol production typical of Cushing syn-
drome. For example, the absence of a diurnal rhythm of 
cortisol production is consistent with autonomous cor-
tisol production from Cushing syndrome [23], specifically 
Cushing disease [24] and can be assessed by measuring 
midnight salivary cortisol, midnight serum cortisol, or 
urine free cortisol [2]. However, the evaluation of altered 
circadian rhythm of cortisol in the setting of autono-
mous production is not sensitive for detection of SCS [2, 
25, 26]. The late-night salivary cortisol is more sensitive 
for detecting Cushing syndrome [27]. The measurement 
of urine free cortisol does not appear to be a sensitive 
screening test for SCS [2], since the increased cortisol 
production in SCS does not usually exceed the binding 
capacity of plasma for cortisol leading to urine free cor-
tisol that is typically normal [2, 7].
The atrophy of contralateral adrenal gland in the 
setting of unilateral cortisol-producing adenoma is 
a relatively well-known event due to the decrease in 
ACTH production [28]. Applying techniques such as 
multidetector CT [28], cholesterol scintigraphy [13, 21, 
29, 30], or PET-CT using 18F-FDG [14, 31], may help 
lateralizing the cortisol-producing adenoma in a patient 
with bilateral adrenal mass. However, contralateral at-
rophy does not necessarily happen in patients with SCS. 
In addition, suppression of ACTH may lead to reduction 
in size of a contralateral cortisol-producing adenoma and 
hence create the appearance of a unilateral tumor on CT 
imaging, but with bilateral overproduction of cortisol. 
Ueland et  al reported 9 patients with unilateral nodule 
on CT scan who had had bilateral cortisol production 
after AVS study [21].
Generally, AVS provides useful information to lateralize 
the source of cortisol production. However, we may face 
some limitations, which requires better understanding of 
AVS pitfalls, to avoid unnecessary adrenalectomy. Acharya 
et al reported 8 cases with ACTH-independent Cushing syn-
drome with bilateral adrenal masses and successful catheter-
ization showed a cortisol lateralization ratio ≤ 2 in 7 cases, 
suggesting bilateral cortisol overproduction. However, 3 of 
8 patients underwent unilateral adrenalectomy based on 
size of adrenal lesion and remission was seen in 1 case [16].
These data suggest that AVS is the best method for 
lateralizing the source of cortisol-producing adenoma 
but the current lateralizing criteria might not detect 
unilateral autonomous cortisol production in cer-
tain situations. Hypothetically, the proximity of the 
Table 2. Results of Adrenal Venous Sampling After 4-mg Overnight Dexamethasone Suppression

















Right AV  
2.3 cm nodule 
12 8.2 662 1.50 1.558 55.2 3.8
Left AV  
3.5 cm nodule 
4.9 3.7 1031 <0.028 210.4
PV (femoral vein) <0.2 < 0.2 80 0.194 NA NA NA
Abbreviations: AV, adrenal veins; AVS, adrenal venous sampling; NA, not applicable; PV, peripheral veins.
AV:PV metanephrine ratio > 12 indicates correct adrenal vein position and successful catheterization [22].
AV:PV cortisol gradient distinguishes cortisol-producing conditions. The gradient ≤3.3 suggests nonsecretory adenoma, between 4.1 and 6.4 is associated with 
adrenal hyperplasia, and >6.5 is consistent with adrenal adenoma [17, 18].
A side-to-side (high-side to low-side) adrenal vein cortisol gradient (cortisol lateralization ratio) >2.3 suggests unilateral cortisol overproduction, while a gra-
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catheter to the adrenal gland and co-secretion of other 
hormones, such as aldosterone and DHEAS, can af-
fect cortisol concentration [17, 32]. The usual method 
to correct the dilution changes is using the ratio of 
cortisol to aldosterone, DHEAS, or catecholamines 
[33]. However, co-secretion of aldosterone and cor-
tisol from different adrenals [34, 35] or same adrenal 
gland [32] can affect the result of the cortisol to al-
dosterone ratio. In addition, the incidence of adenoma 
with co-secretion of cortisol and aldosterone may be 
higher than earlier thought [36, 37]. Furthermore, AVS 
results showed that cortisol secretion from adrenal vein 
of patients without autonomous cortisol secretion has 
variation. Even measurement of the adrenal androgens, 
androstenedione and DHEA, may help in correcting the 
side-to-side gradient [38], but co-secretion of andro-
gens in the SCS patient [32] will potentially interfere 
with this correction. The benefits of using catechol-
amine for correction is more important (Table 3), as 
co-secretion of aldosterone and other steroids [32] pre-
cludes applying the cortisol to aldosterone or cortisol 
to DHEAS ratio for interpreting the AVS outcomes. 
In addition, the shorter half-life of aldosterone (20 
minutes) versus that of cortisol (60-70 minutes) is a 
limitation [33]. However, half-life for the fractionated 
metanephrines (60-105 minutes for free metanephrine, 
and 95 minutes for normetanephrine) [39] is longer 
than aldosterone and comparable to cortisol (60-70 
minutes) [33]. Furthermore, with metanephrine and 
normetanephrine, especially metanephrine, plasma 
levels are less responsive to sympathoadrenal stimu-
lation [40]. Other catecholamines, such as adrenaline 
and noradrenaline, have shorter half-lives (just a few 
minutes) [39, 41] and are not good options for over-
coming the dilution changes of cortisol concentration. 
It is important to mention that pheochromocytoma al-
ters the cortisol concentration [42] and co-secretion 
of catecholamines with cortisol may happen in the 
setting of an ACTH- or corticotropin-releasing hor-
mone–producing pheochromocytoma [43], which is a 
rare condition that can easily be identified during bio-
chemical workup for adrenal incidentaloma detectable 
by measuring fractionated catecholamines and ACTH. 
Therefore, side-to-side cortisol to metanephrine ratio 
comparison is useful for lateralization, because of the 
possible changes in concentration of cortisol during the 
AVS. We must also consider that applying dexametha-
sone before intervention can diminish the effect of 
stress during intervention [33, 44] on cortisol secretion 
by suppressing ACTH.
Based on our case experience and literature review 
(Table 3), we propose an algorithm taking into consider-
ation cortisol to metanephrine ratio for selecting candi-
dates for unilateral adrenalectomy (Fig. 1). Patients with 
unilateral adenoma and contralateral adrenal atrophy in 
the setting of clinical and paraclinical findings suggestive 
for SCS should receive unilateral adrenalectomy after con-
sidering the benefits and risks of surgical intervention. If a 
patient has bilateral adenoma, then AVS is the best method 
to confirm the source of cortisol production and avoiding 
unnecessary surgery. An AV:PV metanephrine ratio  >  12 
suggests successful catheterzation. An AV:PV cortisol gra-
dient > 6.5 is consistent with cortisol-producing adenoma 
and a high to low cortisol gradient  >  2.3 is compatible 
with unilateral cortisol-producing adenoma [17, 21, 33]. 
If the AV:PV cortisol gradient is < 6.5 or high to low cor-
tisol gradient is < 2.3, we suggest measuring high to low 
cortisol/metanephrine ratio gradient. High to low cor-
tisol/metanephrine ratio gradient > 2.3 suggests unilateral 
cortisol-producing adenoma. The proximity of the catheter 
to adrenal gland is a possible reason for the dilution dif-
ferences and cortisol to metanephrine ratio may help to 
correct the dilution differences. Cosrtisol to aldosterone 
ratio [33] or cortisol to androrgen [38] ratio may also help 
lateralizing the source of cortisol production but because 
of the co-secretion of other hormones [32], which can af-
fect the concentration of cortisol, aldosterone, and other 
plama steroids, making the interpretation of lateralization 
more difficult. However, the co-secretion of metanephrine 
and cortisol form an adrenal adenoma is rare [45-48] and 
associated pheochromocytoma can be ruled out with serum 
and 24-hour urine measurements. In addition, the current 
algorithm (Fig. 1) is based on limited experience with a few 
patients and needs validation in a bigger study.
Conclusion
AVS sampling is the best method to lateralize the source of 
cortisol production in SCS patients with suspected bilateral 
nodules or sources of cortisol. In certain situations, if the 
cortisol lateralization ratio does not help in lateralization of 
cortisol hypersecretion, then the cortisol to metanephrine 
ratio would be another option to find the major source of 
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